Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

However, in people with type 2 diabetes (T2D), glucagon levels are often elevated, contributing to difficulties in controlling blood sugar. The study provides new insights into how G6PC2, a gene ...

The venture aims to advance MeiraGTx’s Parkinson’s gene therapy through Phase III trials with up to $430m in funding from ...

display severe pancreatic hypoplasia caused by depletion of pancreatic epithelial precursors due to accelerated differentiation of post-mitotic endocrine cells expressing glucagon. Moreover ...